Nimesulide was
launched in Italy for the first time as Aulin and Mesulid in 1985 and
is presently available in more than 50 countries worldwide in
different trademarks.
Its multifactorial
mode of action gives it a unique and broad action on inflammatory
processes.It
is available in the market in various like tablets (100 mg),
granules for oral suspension (100 mg), suppositories (200 mg) and gel
(3%).
The Gel needed to be
applied is three to four times per day depending on the dimension of
the affected size and response. Medicalcare ought to be reviewed
after 4 weeks.
Trademarks
of Nimesulide include of Sulide, Nimalox, Nimesil, Nimulid, Nicip,
Nimcap, Nise, Sulidene and Zolan e.t.c.Nimulid Transgel is indicated
for post-traumatic inflammation, acute musculoskeletal disorders
including sprains, strains, tendinitis, tenosynovitis, low back pain,
periarthritis (shoulder pain) and osteoarthritis (joint pains),
stiffness.
Nimesulide has
superior gastrointestinal safety as compared to other NSAIDs with
multi factorial approach for treating post-traumatic inflammation,
acute musculoskeletal disorders including sprains, strains,
tendinitis, tenosynovitis, low back pain, periarthritis (shoulder
pain) and osteoarthritis (joint pains), stiffness.
No comments:
Post a Comment